Core C: Immunologic Monitoring and Cellular Products Laboratory (IMCPL) This laboratory is a specialized facility at the University of Pittsburgh Cancer Institute (UPCI), which is dedicated to the state-of-the-art evaluation of immune responses prior to, during and after therapeutic interventions in patients with cancer. In addition to generating cellular products for human therapy, it also provides services for tissue procurement and processing. In its role as Core C for this PPG, the IMCPL will assume responsibility for supporting the immunotherapy-based clinical trials proposed by the projects. Core C, functioning as a cGMP facility, will culture and characterize dendritic cells (aDC1) for patient therapy and prepare vaccines by loading these aDC1 with apoptotic tumor cells (ATC) (colorectal cancer (Project 1 and 4) and melanoma (Project 1)) for therapy. Core C will be responsible for quality and sterility of the aDC1- based vaccines. Potency of aDC1 products will be measured, using the IL-12p70 production assay. Core C will also procure and process all body fluids and tissues harvested in the course of the clinical trials. Tumor specimens obtained at the time of surgery or biopsy tissues will be processed for use in vaccines or will be banked for immunohistochemistry to be performed by Core B. Core C, serving as a fully certified immunologic monitoring facility, will monitor immune responses to the administered vaccines by performing ELISPOT assays and tetramer analyses. Core C will also be prepared to assist the PPG investigators in implementing assays necessary for evaluation of immunologic responses to vaccines. The Core will ensure that all cellular products it generates and samples it collects are accompanied by appropriate documentation that will permit linking laboratory analyses with clinical results. Core C will also provide assistance in preparation of IND submissions. The Core laboratory has a long history of collaboration with all of the investigators, and in the context of the proposed clinical and pre-clinical studies will be entirely dedicated to the support of this PPG.

Public Health Relevance

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94
Guo, Z S; Bartlett, D L (2014) Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 21:261-3
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847-57
Hamilton, Ronald; Krauze, Michal; Romkes, Marjorie et al. (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:2737-46
Kohanbash, Gary; McKaveney, Kayla; Sakaki, Masashi et al. (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-*. Cancer Res 73:6413-23
Okada, Hideho; Scheurer, Michael E; Sarkar, Saumendra N et al. (2013) Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci 1284:17-23
Sampath, Padma; Li, Jun; Hou, Weizhou et al. (2013) Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 21:620-8
Yeung, Jacky T; Hamilton, Ronald L; Ohnishi, Koji et al. (2013) LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 19:1816-26
Bartlett, David L; Liu, Zuqiang; Sathaiah, Magesh et al. (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103

Showing the most recent 10 out of 37 publications